Protagenic Therapeutics Inc. has announced an update regarding its business combination with Phytanix Bio Inc. The company recently generated $3.1 million in cash through warrant exchanges and exercises, which will support its operational needs and progress its peptide-based drug candidates targeting stress-related and central-nervous-system disorders. This merger brings together a total of six complementary drug programs, covering areas such as stress disorders, epilepsy, and obesity, under one entity. The collaboration aims to enhance the development of innovative treatments using both peptides and cannabinoid-like molecules.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.